Latest:
Exciting NSCLC Data Updates from ESMO 2022
The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
B. Hilda Ye, PhD
Latest:
Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic Features
Adult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.
Donna Catamero, ANP-BC OCN, CCRC
Donna Catamero, ANP-BC OCN, CCRC is Associate Director of Myeloma Research at Icahn School of Medicine at Mount Sinai Hospital.
Latest:
Catamero on Challenges of Community-Based Administration of Bispecifics and CAR T-Cell Therapy in Myeloma
Donna Catamero, ANP-BC, OCN, CCRC, discusses the challenges community-based clinicians face in delivering bispecific antibodies and CAR T-cell therapy for multiple myeloma.
Tim Eisen, MB BChir, PhD
Latest:
How Academia and Industry Intersect to Improve Oncology Research and Patient Care: With D. Ross Camidge, MD, PhD; and Tim Eisen, MB BChir, PhD
Drs Camidge and Eisen discuss Dr Eisen's dual career in academia and industry, the importance of aligning academic and clinical strengths, and how industry experience can enhance drug development.
Anna R. Minchom MD, BCh, MB, MRCP
Latest:
Dr Minchom on the Safety of Subcutaneous Amivantamab in Advanced Solid Tumors
Anna R. Minchom MD, BCh, MB, MRCP, discusses the safety and recommended phase 2 doses of subcutaneous amivantamab-vmjw for patients with advanced solid tumors in the phase 1b PALOMA trial.
Paolo Tarantino, MD
Paolo Tarantino, MD is an Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and Harvard Medical School.
Latest:
Clinical Significance of ADC in Breast Cancer: Updates Presented at ESMO 2025
Experts analyze groundbreaking antibody drug conjugate findings from ESMO 2025, highlighting their impact on breast cancer treatment strategies and patient care.
Jayesh Desai, MBBS, FRACP
Latest:
Phase IB Study of GDC-6036 in Combination with Cetuximab in Patients With Colorectal Cancer (CRC) With KRAS G12C Mutation
Jayesh Desai, MBBS, FRACP, shares data from a phase IB study investigating KRAS G12C inhibitor GDC-6036, or divarasib, in combination with cetuximab for the treatment of patients with colorectal cancer.
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, is an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Latest:
Dr Ku on the Rationale for Evaluating JNJ-90014496 in Relapsed/Refractory LBCL
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, details the rationale for assessing a dual bispecific CAR T-cell therapy in relapsed/refractory LBCL.